When Oxford Nanopore Technologies spun out of a lab idea, few could have predicted it would become the UK's first unicorn to list on public markets—or that its DNA sequencing technology would eventually reshape how scientists track disease, diagnose patients, and accelerate drug discovery worldwide. The company's 18-year journey from university research project to globally transformative biotech firm offers a masterclass in what it takes to turn brilliant science into real-world impact at scale.
On 3 June 2026, Oxford's Green Templeton College will host a fireside chat featuring Zoe McDougall and Dr Mark Bruce from Oxford Nanopore Technologies, speaking with Thomas Hellmann, Professor of Entrepreneurship and Innovation at the Said Business School. Their conversation arrives at a pivotal moment—as the world grapples with urgent health challenges and the role of biotechnology in solving them. The question they'll explore is deceptively simple but profound: what does it actually take to turn a groundbreaking scientific idea into a technology that reshapes an entire scientific ecosystem?
Oxford Nanopore's answer lies in fusion. The company wove together disciplines that rarely speak to each other—chip design, electrochemistry, and single-molecule sensing—to create devices that make DNA and RNA analysis faster, richer, and more accessible than ever before. What began as ambitious lab work eventually found application across pathogen surveillance, clinical genomics, and as a backbone for biopharma industries. This breadth of impact distinguishes Oxford Nanopore from countless other startups that solve elegant problems for narrow audiences. Instead, the company's technology became infrastructure—the kind of platform others build upon.
The speakers will trace this evolution unflinchingly, examining both breakthroughs and the very real challenges of scaling a science-led company. They'll reflect on how Oxford's unique entrepreneurial environment—its density of talent, willingness to experiment, and constellation of support networks—shaped the company's growth. But they'll also highlight something less often discussed: how Oxford Nanopore didn't simply extract value from Oxford. The company grew symbiotically alongside the technology and commercialisation ecosystem it helped create, strengthening the broader innovation culture in the process.
This conversation matters because the global health landscape demands exactly this kind of thinking. In an era when biotechnology and digital health are rapidly expanding, and when crises from pandemic response to antimicrobial resistance test our preparedness, the conditions that allow science to flourish at scale become a public concern. Few institutions bring together health innovation, entrepreneurship, and policy in sustained dialogue. The Green Templeton Lectures series—of which this is the third installment in 2026—aims to fill that gap, creating space for researchers, practitioners, and future leaders to exchange ideas meaningfully.
The lecture itself is free and open to all who register. It concludes with a drinks reception, an informal space where the conversation can continue. In hosting this event, Green Templeton College signals that the question of how discovery becomes impact—how determination and collaboration turn ideas into systems change—isn't niche academic territory. It's essential groundwork for the future of health itself.